Duke University Medical Center is conducting a study to determine whether or not treatment with ustekinumab improves symptoms of Crohn’s disease, and to look for any possible side effects. Ustekinumab is an "investigational drug," which means that it’s still being tested in research and has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn’s disease.

Eligibility Criteria
To participate in this study, you must be an adult who meets the following criteria:
• Has active Crohn’s disease
• Screening laboratory values, test, and physical exam within acceptable ranges

Duration
Your participation in this study will last for nine to13 weeks (depending on how long you are in the screening period). You will visit your study doctor five times in this study. At the final visit you will be asked to participate in an additional 44-week (maintenance) study and a long-term extension study that will last approximately four years.


For more information, contact Kim Meyer at 919-684-0742 or kim.meyer@duke.edu.

For more information, contact Heather Kuehn at 668-1681.